Hemogenyx Pharmaceuticals PLC Announces HEMO-CAR-T pre-IND Meeting Request
Hemogenyx Pharmaceuticals has announced that the FDA has deferred its pre-Investigational New Drug meeting for its lead product candidate, HEMO-CAR-T, until May 2022. This change is due to the FDA prioritizing COVID-19 related work, but the company emphasizes that this will not delay HEMO-CAR-T's development or its IND filing. Additionally, progress continues positively on the CDX bispecific antibody for acute myeloid leukaemia and the CBR platform technology for viral diseases. The CEO reassures that the IND application remains on track despite the changes.
- No anticipated impact on the IND filing for HEMO-CAR-T despite FDA meeting deferment.
- Ongoing positive progress on the development of HEMO-CAR-T, CDX bispecific antibody, and CBR platform.
- FDA's deferment of the pre-IND meeting may cause uncertainty among investors.
LONDON, UK / ACCESSWIRE / February 16, 2022 / Hemogenyx Pharmaceuticals plc ("Hemogenyx Pharmaceuticals" or the "Company") (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, has received notification from the Food and Drugs Administration ("FDA") that the proposed pre-Investigational New Drug ("pre-IND") meeting relating to the Company's lead product candidate Chimeric Antigen Receptor ("CAR") T-cells ("HEMO-CAR-T") is to be deferred until May 2022 as a result of a general FDA policy prioritizing work on COVID-19. The deferment of the meeting is not causing any delay in the development of the product candidate. In the meantime, the process will be dealt with by written responses by the FDA to a submission which is now being refined. A pre-IND meeting will then be necessary only if the written responses leave any matters unresolved. In light of this written process now implemented by FDA, there is no anticipated impact from the deferment on the IND filing for HEMO-CAR-T.
As noted above, the process for pre-IND meetings has been amended by the FDA on a general basis, with the Agency stating as follows: "In response to the Coronavirus Disease 2019 (COVID-19) public health emergency, FDA's Center for Biologics Evaluation and Research (CBER) has taken steps to prioritize work that advances the nation's response during this national emergency."
In the meantime, work on manufacturability, quality, safety and other key parts of the development HEMO-CAR-T continue in an encouraging manner.
In addition, positive progress continues in relation to the Company's CDX bispecific antibody product candidate for the treatment of acute myeloid leukaemia, as well as its CBR platform product candidate, a novel cell-based platform technology for the treatment of emerging viral diseases and certain types of cancer. The Company will continue to notify shareholders as key stages with respect to all of its product candidates are reached.
Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: "The process toward our IND application remains on track and the change in the FDA's process is not expected to affect the outcome of the IND application or timetable for clinical trials."
About AML and CAR-T Therapy
AML, the most common type of acute leukemia in adults, has poor survival rates (a five-year survival rate of less than
CAR-T therapy is a treatment in which a patient's own T-cells, a type of immune cell, are modified to recognize and kill the patient's cancer cells. The procedure involves: isolating T-cells from the patient; modifying the isolated T-cells in a laboratory using a CAR gene construct (which allows the cells to recognize the patient's cancer); amplifying (growing to large numbers) the newly modified cells; and re-introducing the cells back into the patient.
Enquiries:
Hemogenyx Pharmaceuticals plc | https://hemogenyx.com |
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder | headquarters@hemogenyx.com |
Peter Redmond, Director | peter.redmond@hemogenyx.com |
SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
Matthew Johnson, Vadim Alexandre, Adam Cowl | |
Peterhouse Capital Limited | Tel: +44 (0)20 7469 0930 |
Lucy Williams, Duncan Vasey, Charles Goodfellow | |
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company (LSE:HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.
The Company is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development.
For more than 50 years, bone marrow transplantation has been used to save the lives of patients suffering from blood diseases. The risks of toxicity and death that are associated with bone marrow transplantation, however, have meant that the procedure is restricted to use only as a last resort. The Company's technology has the potential to enable many more patients suffering from devastating blood diseases such as leukemia and lymphoma, as well as severe autoimmune diseases such as multiple sclerosis, aplastic anemia and systemic lupus erythematosus (Lupus), to benefit from bone marrow transplantation.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Hemogenyx Pharmaceuticals PLC
View source version on accesswire.com:
https://www.accesswire.com/689004/Hemogenyx-Pharmaceuticals-PLC-Announces-HEMO-CAR-T-pre-IND-Meeting-Request
FAQ
What is the reason for Hemogenyx Pharmaceuticals' pre-IND meeting deferral?
Will the deferment of the pre-IND meeting impact the HEMO-CAR-T development timeline?
What is the current status of HEMO-CAR-T according to the latest press release?
What other product candidates are being developed by Hemogenyx Pharmaceuticals?
